PRK vs EVO ICL: Which Should I Choose? | Lasik Awards

Quick Answer

PRK is the better choice for patients with mild to moderate myopia (-1.00 to -8.00 D), adequate corneal thickness, and no significant dry eye. EVO ICL (Implantable Collamer Lens) is the better choice for patients with high myopia (up to -20.00 D), thin corneas, dry eye disease, or prescriptions outside the safe range for corneal ablation. Both deliver excellent visual outcomes. The decision is driven almost entirely by your corneal profile and prescription.

Detailed Explanation

PRK and EVO ICL are both legitimate, FDA-approved vision correction procedures — but they are not interchangeable. They work through fundamentally different mechanisms and serve different patient populations. Many patients who ask “which is better?” are actually asking the wrong question. The right question is: “Which is appropriate for my specific eye?”

How Each Procedure Works

PRK removes the corneal epithelium and uses an excimer laser to reshape the underlying stroma, permanently changing the eye’s focusing power. Tissue is removed and does not grow back. Recovery takes weeks to months.

EVO ICL implants a flexible, biocompatible Collamer lens between the natural lens of the eye and the iris. No corneal tissue is removed. The lens sits invisibly inside the eye. Vision change is immediate. The lens is removable and replaceable if prescription changes or complications require it.

Prescription Range

This is often the primary determining factor.

PRK’s upper safe limit is governed by how much tissue can be ablated while maintaining an adequate residual stromal bed. EVO ICL has no such constraint — it adds focusing power without removing tissue.

Corneal Thickness

PRK requires adequate corneal thickness. The residual stromal bed after ablation must remain above 250 microns. Patients with thin corneas (below 500 microns at baseline) may have insufficient tissue for PRK, particularly at higher prescriptions.

EVO ICL does not require corneal tissue removal. Thin corneas are not a contraindication. However, EVO ICL requires sufficient anterior chamber depth (the space between the cornea and natural lens) to safely accommodate the implant. Patients with shallow anterior chambers may not qualify for ICL.

Dry Eye

PRK temporarily reduces corneal nerve density, worsening dry eye for 3–6 months post-surgery. For patients with pre-existing dry eye disease, this can be a significant problem. EVO ICL does not affect corneal nerves and is associated with minimal impact on tear film. It is generally the recommended option for patients with clinically diagnosed dry eye.

Recovery Timeline

PRK recovery is the major practical disadvantage. Vision stabilizes over 1–3 months. Discomfort is meaningful during the first week.

EVO ICL recovery is dramatically faster — most patients achieve stable, clear vision within 24–48 hours. Discomfort after ICL is minimal and short-lived.

Reversibility

PRK is permanent. Corneal tissue removed during ablation is not restored. EVO ICL is theoretically reversible — the lens can be removed or exchanged. This is rarely done electively, but the option exists.

Long-Term Outcomes Comparison

Both procedures have strong clinical evidence bases. PRK has decades of outcomes data. EVO ICL has been in clinical use since the early 1990s and received FDA approval in the U.S. in 2022.

Published studies comparing PRK and ICL outcomes consistently show:

EVO ICL produces slightly higher rates of 20/20 or better in the first 12 months, attributed to the absence of haze and healing variability
PRK outcomes in the 5–10 year range remain excellent and converge closely with ICL results
ICL patients report marginally higher immediate quality-of-vision scores, particularly in low-light conditions

Cost

PRK typically costs $2,000–$3,500 per eye. EVO ICL typically costs $3,500–$5,000 per eye. The ICL premium reflects the cost of the implant device itself, additional surgical complexity, and a longer pre-operative evaluation process. Both are considered elective by most insurance carriers and are not covered by standard medical plans.

For outstanding surgeons evaluated across both PRK and advanced refractive procedures, visit PRK Surgery Awards.

Important Considerations

The best procedure is the one your surgeon recommends based on your diagnostics — not the one you read about online. Some patients arrive at consultations having decided they want a specific procedure. A thorough pre-operative evaluation may confirm their choice or redirect them. Trust the evaluation over the preference.

EVO ICL is not available at every center. Not every ophthalmologist or refractive surgery center offers ICL implantation. Patients who are directed toward ICL should ensure their surgeon performs this procedure regularly — it is not the same skill set as laser refractive surgery.

Consider your long-term options. Choosing ICL preserves your corneal tissue, leaving PRK available as a future option if needed. Choosing PRK first consumes tissue that cannot be replaced.

Surgeon experience is equally important for both. ICL implantation by low-volume surgeons carries higher rates of ICL sizing errors, elevated intraocular pressure, and cataract formation. Volume and experience matter.

What to Do Next

1. Get a full evaluation at a center offering both procedures. Centers that offer only PRK have a structural incentive to recommend PRK. A center offering both can make a neutral recommendation.

2. Ask specifically about your anterior chamber depth. This is the ICL-specific measurement that determines eligibility. It is measured during the pre-operative evaluation.

3. Review your prescription against the PRK safe treatment range. If you are above -8.00 D, ICL is likely your primary option regardless of other factors.

4. Understand the PRK consultation process. What Happens During the PRK Consultation outlines the evaluation needed before any procedure decision.